Race against time: new drug aims to slow muscle loss in boys with devastating disease
NCT ID NCT04587908
Summary
This study is testing whether an oral drug called TAS-205 can help slow the progression of Duchenne muscular dystrophy (DMD). It involves about 104 boys and young men with DMD, split into groups based on whether they can still walk. The main goal is to see if the drug improves the time it takes to stand up from the floor over 52 weeks and to check its safety. After the initial year, participants can choose to continue taking the drug in an open-label extension.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A site selected by Taiho Pharmaceutical Co., Ltd.
Aichi, Japan
-
A site selected by Taiho Pharmaceutical Co., Ltd.
Fukuoka, Japan
-
A site selected by Taiho Pharmaceutical Co., Ltd.
Hokkaido, Japan
-
A site selected by Taiho Pharmaceutical Co., Ltd.
Osaka, Japan
-
A site selected by Taiho Pharmaceutical Co., Ltd.
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.